Oumzil Khalid, Ramin Michael A, Lorenzato Cyril, Hémadou Audrey, Laroche Jeanny, Jacobin-Valat Marie Josée, Mornet Stephane, Roy Claude-Eric, Kauss Tina, Gaudin Karen, Clofent-Sanchez Gisèle, Barthélémy Philippe
University of Bordeaux, ARNA laboratory , F-33000 Bordeaux, France.
INSERM, U869, ARNA laboratory , F-33000 Bordeaux, France.
Bioconjug Chem. 2016 Mar 16;27(3):569-75. doi: 10.1021/acs.bioconjchem.5b00590. Epub 2016 Jan 26.
Although the application of nanotechnologies to atherosclerosis remains a young field, novel strategies are needed to address this public health issue. In this context, the magnetic resonance imaging (MRI) approach has been gradually investigated in order to enable image-guided treatments. In this contribution, we report a new approach based on nucleoside-lipids allowing the synthesis of solid lipid nanoparticles (SLN) loaded with iron oxide particles and therapeutic agents. The insertion of nucleoside-lipids allows the formation of stable SLNs loaded with prostacycline (PGI2) able to inhibit platelet aggregation. The new SLNs feature better relaxivity properties in comparison to the clinically used contrast agent Feridex, indicating that SLNs are suitable for image-guided therapy.
尽管纳米技术在动脉粥样硬化领域的应用尚属新兴领域,但仍需要新的策略来解决这一公共卫生问题。在此背景下,人们逐渐对磁共振成像(MRI)方法展开研究,以实现图像引导治疗。在本论文中,我们报告了一种基于核苷脂质的新方法,该方法能够合成负载氧化铁颗粒和治疗剂的固体脂质纳米粒(SLN)。核苷脂质的插入使得能够形成负载前列环素(PGI2)的稳定SLN,PGI2能够抑制血小板聚集。与临床使用的造影剂菲立磁相比,新型SLN具有更好的弛豫特性,这表明SLN适用于图像引导治疗。